Search results
ASCO 2024: What's New in Breast Cancer Research?
Medscape· 20 hours agoDrs Alexandra Thomas and Virginia Kaklamani discuss highlights in breast cancer research from the ASCO 2024 Annual Meeting.
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
Zacks via Yahoo Finance· 6 days agoJ&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority...
Moderna-Merck skin cancer vaccine shows survival benefit in long-term follow-up
Reuters· 4 days ago, opens new tab said on Monday their cancer vaccine in combination with blockbuster cancer therapy...
Merck, Moderna Drug Combo Shows Improved Survival in Skin Cancer Trial
Morningstar· 3 days agoModerna and Merck said they saw positive results from a Phase 2b study evaluating mRNA-4157 in combination with Keytruda in patients with high-risk skin cancer that was surgically ...
Why Is OPKO Health (OPK) Up 12.8% Since Last Earnings Report?
Zacks via Yahoo Finance· 10 hours agoRevenues from the transfer of intellectual property and others totaled $8.7 million, down from $64.8...
MilliporeSigma Announces Siren Biotechnology As Winner Of Its North American Advance Biotech Grant
BioresearchOnline· 3 days agoMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany,...
Experimental mRNA vaccines gain steam with promising cancer trial results
Semafor via Yahoo News· 3 days agoInsights from TIME, The Washington Post, MIT Technology Review The News Pharmaceutical giants...
Summit Therapeutics, AstraZeneca And More From The Year’s Biggest Cancer Conference
Forbes· 1 day agoThe conference was a big one for Summit Therapeutics, which saw its stock price more than double...
Some drugmakers to cap cost of asthma inhalers at $35 a month
NBC News via Yahoo News· 6 days agoStarting Saturday, the cost of inhalers will fall for many Americans, as new out-of-pocket price...
Why Is Ligand (LGND) Up 4% Since Last Earnings Report?
Zacks via Yahoo Finance· 10 hours agoThe upside was driven by increased royalties from Amgen’s Kyprolis, Jazz Pharmaceuticals’ Rylaze, ...